SSSarah E. Servattalab

Sarah E. Servattalab

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah E. Servattalab has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Expanding Access to Care: Implementation of a Pediatric and Young Adult Laser Hair Removal Program for Hidradenitis Suppurativa

    by Sarah Lee, Sarah Servattalab, Yasin Damji

    Laser hair removal (LHR) is an effective adjunctive therapy for hidradenitis suppurativa (HS), but access is often limited by inconsistent insurance coverage. A retrospective review was conducted of 21 pediatric and young adult patients enrolled in an LHR program for HS at a tertiary children's hospital. Among patients receiving two or more sessions ( n = 20), 86% demonstrated visible hair thinning or reduced hair regrowth on examination, and 81% self‐reported decreased flare severity or frequency, with no adverse events observed. All treatments were ultimately covered by insurance through a standardized prior authorization process, supporting the feasibility of expanding access to LHR for pediatric and young adult patients with HS.

  • Hepatitis B Immunity in Children on Immunomodulators: Implications From a Pediatric Dermatology Cohort and Review of the Literature

    by Adrienne Conza, Racquel A. Bitar, Fiona H. Lynch, Pierre‐Olivier Grenier, Elena B. Hawryluk, Sarah E. Servattalab

    Background/Objectives: This study aims to determine the level of hepatitis B virus (HBV) immunity in patients who had HBV serologic testing prior to starting immunomodulatory medication for dermatologic conditions at a single institution and to review evidence on waning immunity, serologic interpretation, and revaccination. Methods: We performed a retrospective chart review of pediatric and young adult patients initiated on immunomodulatory therapy for dermatologic conditions who had HBV serologic testing prior to initiation. A focused literature review was conducted on durability of HBV immunity, HBV serologies in the context of immunomodulatory medications, and revaccination recommendations. Results: In this cohort of 23 children, roughly 40% lacked HBV serologic immunity. Prior studies demonstrated that antibody‐mediated protection is heterogeneous and anti‐HBs titers decline over time. Existing guidelines are largely derived from adult populations. Evidence regarding revaccination strategies is mixed. Notably, absence of detectable anti‐HBs antibodies does not always equate to loss of immune memory or susceptibility to infection. Conclusions: Anti‐HBs titers are variable and wane over time. Experts agree that patients should receive all recommended vaccinations before starting immunomodulatory therapy and be screened for HBV beforehand, based on adult guidelines. It is uncertain how well these recommendations apply to children, who generally have lower HBV risk and prevalence. Guidance is needed on how to manage pediatric patients without serologic evidence of HBV immunity before beginning biologic treatments.

  • Disparities in care of infantile hemangiomas: A retrospective cohort study measuring the impact of area deprivation, race, and ethnicity

    by Sarah E. Servattalab, Katherine Barahona Paz, Shannon McLaughlin, Alexandra Epee-Bounya, Jennifer T. Huang, Pierre-Olivier Grenier

  • Leg Length Discrepancy in Patients With Lower Extremity Cutis Marmorata Telangiectatica Congenita: A Multicenter Retrospective Study

    by Racquel A. Bitar, Sarah E. Servattalab, Marilyn G. Liang, Samantha Spencer, Aliza Ray, Carter R. Petty, Besiana P. Beqo, Griffin Stockton Hogrogian, Albert C. Yan, James R. Treat, et al.

    Objectives: To assess the frequency of leg length discrepancy (LLD) in patients with lower extremity cutis marmorata telangiectatica congenita (CMTC), describe associated findings, and characterize LLD management. Methods: We conducted a retrospective chart review of patients diagnosed with lower extremity CMTC by dermatology and evaluated by orthopedics at Boston Children's Hospital and Children's Hospital of Philadelphia from 1997 to 2024. LLD was assessed by orthopedic examination and/or radiographic imaging. Major LLD was defined as ≥ 2 cm at any age, or between 1 and 2 cm in children 4 years old or younger. Mild LLD was defined as < 2 cm, except when ≥ 1 cm was present by age 4. Kaplan–Meier analysis estimated the probability of developing major LLD by age 15. Results: Twenty‐eight patients with lower extremity CMTC were included. LLD was identified in 12 of 28 patients (43%), including 8 confirmed radiographically and 4 diagnosed by clinical assessment alone. Two (7%) were classified as major and 10 (36%) as mild. Limb hypoplasia occurred in 18 of 28 patients (64%). Kaplan–Meier analysis estimated a 7.1% cumulative risk of major LLD by age 15. Three of 12 patients (25%) with LLD were prescribed shoe lifts. Conclusion: LLD is common among patients with lower extremity CMTC. Early orthopedic assessment may facilitate timely intervention.


  • Successful Use of Adalimumab for Dissecting Cellulitis in a Pediatric Patient With Keratitis–Ichthyosis–Deafness ( KID ) Syndrome

    by Sarah Lee, Sarah Servattalab, Yasin Damji

    Dissecting cellulitis of the scalp (DCS) is a chronic inflammatory condition characterized by painful, draining nodules and progressive, scarring alopecia. It is often refractory to treatment, and there are currently no FDA‐approved therapies. We present a case of a 15‐year‐old boy with keratitis–ichthyosis–deafness (KID) syndrome and DCS who experienced significant clinical response to treatment with adalimumab after failing multiple courses of oral antimicrobials, surgical interventions, intralesional corticosteroids, and topical therapies. Treatment with adalimumab led to reduction in drainage and pain and visible hair regrowth, highlighting its therapeutic potential in refractory, pediatric DCS including in the setting of syndromic skin disease.

  • Open Access

    Atrophic, translucent plaque on the scalp of a newborn

    by Racquel A. Bitar, Sarah E. Servattalab, Yasin Damji

  • Regional Infantile Hemangiomas Associated With Raynaud Phenomenon

    by Racquel A. Bitar, Sarah E. Servattalab, Lauren A. Henderson, Megan M. Perron, Amir H. Taghinia, Marilyn G. Liang

    Regional (segmental) infantile hemangioma (IH) can be associated with arterial anomalies, as seen in PHACE (posterior fossa anomalies, hemangioma, arterial anomalies, cardiac anomalies, and eye anomalies) and LUMBAR (lower body infantile hemangiomas, urogenital anomalies and ulceration, myelopathy, bony deformities, anorectal malformations and arterial anomalies, and rectal anomalies) associations. We describe two patients with a regional IH on the hand associated with Raynaud phenomenon. We hypothesize that Raynaud phenomenon in the setting of a regional IH may be due to post‐traumatic vasospastic response, arterial anomalies, cutaneous atrophy due to the IH, and/or changes in vasomotor regulation.